Parkinson's Disease TREM2 Targeting Companies
Overview
flowchart TD
companies_pd_trem2_targeting_c["PD TREM2 Targeting Companies"]
style companies_pd_trem2_targeting_c fill:#4fc3f7,stroke:#333,color:#000
companies_pd_trem2_t_0["Scientific Rationale"]
companies_pd_trem2_targeting_c -->|"includes"| companies_pd_trem2_t_0
style companies_pd_trem2_t_0 fill:#81c784,stroke:#333,color:#000
companies_pd_trem2_t_1["TREM2 Biology in Parkinsons Disease"]
companies_pd_trem2_targeting_c -->|"includes"| companies_pd_trem2_t_1
style companies_pd_trem2_t_1 fill:#ef5350,stroke:#333,color:#000
companies_pd_trem2_t_2["Biomarker Potential"]
companies_pd_trem2_targeting_c -->|"includes"| companies_pd_trem2_t_2
style companies_pd_trem2_t_2 fill:#ffd54f,stroke:#333,color:#000
companies_pd_trem2_t_3["Companies with PD TREM2 Programs"]
companies_pd_trem2_targeting_c -->|"includes"| companies_pd_trem2_t_3
style companies_pd_trem2_t_3 fill:#ce93d8,stroke:#333,color:#000
companies_pd_trem2_t_4["Alector"]
companies_pd_trem2_targeting_c -->|"includes"| companies_pd_trem2_t_4
style companies_pd_trem2_t_4 fill:#4fc3f7,stroke:#333,color:#000
companies_pd_trem2_t_5["Denali Therapeutics"]
companies_pd_trem2_targeting_c -->|"includes"| companies_pd_trem2_t_5
style companies_pd_trem2_t_5 fill:#81c784,stroke:#333,color:#000
...Parkinson's Disease TREM2 Targeting Companies
Overview
Mermaid diagram (expand to render)
This category page covers biotechnology and pharmaceutical companies developing therapies that target TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) for Parkinson's disease (PD) and related alpha-synucleinopathies. TREM2 is a receptor expressed primarily on microglia in the brain that plays a critical role in phagocytosis, neuroinflammation regulation, and clearance of pathological protein aggregates.
While most TREM2 therapeutic development has focused on Alzheimer's disease, there is growing evidence that TREM2 modulation may also benefit Parkinson's disease patients by:
- Enhancing microglial clearance of alpha-synuclein aggregates
- Modulating neuroinflammatory responses in the substantia nigra
- Supporting dopaminergic neuron survival
- Serving as a biomarker for disease progression (via soluble TREM2 in CSF)
Scientific Rationale
TREM2 Biology in Parkinson's Disease
TREM2 is a cell surface receptor belonging to the immunoglobulin superfamily, primarily expressed on microglia and peripheral macrophages. In neurodegenerative diseases, TREM2 signaling influences several critical microglial functions:
| Function | TREM2 Role in PD |
|----------|-----------------|
| Phagocytosis | Enhances clearance of alpha-synuclein aggregates |
| Neuroinflammation | Modulates pro-inflammatory cytokine production |
| Cell survival | Promotes microglial survival and proliferation |
| Lipid metabolism | Processes lipid ligands from damaged neurons |
Genetic studies have identified TREM2 variants associated with increased PD risk, similar to Alzheimer's disease findings. The R47H variant (rs75932628) has been linked to increased risk in both European and Chinese populations[@christensen2024][@jiang2024].
Biomarker Potential
Soluble TREM2 (sTREM2) in cerebrospinal fluid has emerged as a biomarker for microglial activation in PD. Studies show sTREM2 levels correlate with disease progression and may predict therapeutic response[@zhao2024].
Companies with PD TREM2 Programs
Alector
Pipeline: AL002 (TREM2 agonist)
Alector is a pioneering company in the immuno-neurology space, developing innate immune checkpoint modulators for neurodegeneration. While their lead program AL002 is primarily in Alzheimer's disease trials, the company has acknowledged preclinical work in Parkinson's disease models.
- AL002: Monoclonal antibody TREM2 agonist using Alector Brain Carrier (ABC) platform
- Stage: Phase 2 (INVOKE-1 trial for AD, NCT05189193)
- Partnership: Collaboration with Genentech/Roche
- PD Relevance: Preclinical data in alpha-synuclein models showing enhanced microglial clearance
See [Alector](/companies/alector) for full company profile.
Denali Therapeutics
Pipeline: DNL919, DNL126 (TREM2 agonists)
Denali Therapeutics has a robust TREM2 program leveraging their Brain Transport Vehicle (BTV) platform for enhanced CNS penetration.
- DNL919 (ARS-3601): TREM2 agonist antibody using BTV platform
- Stage: Phase 1 for AD
- DNL126: Next-generation TREM2 activator
- PD Relevance: BTV platform enables better delivery to substantia nigra
See [Denali Therapeutics](/companies/denali-therapeutics) for full company profile.
Vigil Neuroscience
Pipeline: VIG-100, VIG-106 (TREM2 agonists)
Vigil Neuroscience focuses on microglia-targeting therapies for neurodegenerative diseases.
- VIG-100: TREM2 agonist antibody
- Stage: Phase 1
- VIG-106: TREM2 agonist for Phase 1
- PD Relevance: Pipeline positioned for both AD and PD
See [Vigil Neuroscience](/companies/vigil-neuroscience) for full company profile.
Aleza Therapeutics
Pipeline: Research programs in TREM2 modulation for PD
Aleza Therapeutics is developing TREM2-targeted approaches specifically for Parkinson's disease.
- Focus: TREM2 modulation in alpha-synuclein models
- Stage: Preclinical
- PD Relevance: Direct focus on PD rather than AD
See [Aleza Therapeutics](/companies/aleza-therapeutics) for full company profile.
AC Immune
Pipeline: AL002 (in partnership with Genentech)
AC Immune collaborates with Genentech on TREM2 programs.
- AL002: TREM2 agonist
- Stage: Phase 2 (TRAILBLAZER-ALZ 3)
- PD Relevance: Part of broader neurodegenerative program
See [AC Immune](/companies/ac-immune) for full company profile.
Clinical Pipeline Summary
| Company | Drug | Mechanism | Indication | Stage | Clinical Trial |
|---------|------|-----------|------------|-------|----------------|
| Alector/Genentech | AL002 | TREM2 agonist mAb | AD | Phase 2 | NCT05189193 |
| Denali | DNL919 | TREM2 agonist (BTV) | AD | Phase 1 | — |
| Vigil Neuroscience | VIG-100 | TREM2 agonist mAb | PD/AD | Phase 1 | — |
| Vigil Neuroscience | VIG-106 | TREM2 agonist mAb | PD/AD | Phase 1 | — |
Competitive Landscape
TREM2 therapy for PD faces several challenges:
CNS delivery: Getting sufficient antibody concentrations to the substantia nigra
Biomarker development: sTREM2 as a potential patient selection biomarker
Combination approaches: TREM2 modulators may work synergistically with alpha-synuclein targeting therapies
Timing: Determining optimal patient population (early vs. advanced PD)The TREM2 space for PD is earlier than AD, with no dedicated PD Phase 2 trials as of early 2026. However, the strong biological rationale and AD trial learnings position this as a promising approach.
Related Pages
- [TREM2 in Parkinson's Disease Mechanism](/mechanisms/trem2-parkinsons-disease)
- [AD Neuroimmune Checkpoint and TREM2 Pathway Companies](/companies/ad-neuroimmune-checkpoint-trem2-pathway-companies)
- [Parkinson's Disease Neuroinflammation](/mechanisms/neuroinflammation-parkinsons-disease)
- [Alpha-Synuclein Aggregation Mechanisms](/mechanisms/alpha-synuclein-aggregation)
- [Microglia in Neurodegeneration](/cell-types/microglia-neuroinflammation)
References
[Stojkovska et al., Microglia in Parkinson's disease: role of TREM2 (2018)](https://pubmed.ncbi.nlm.nih.gov/29884126/)
[Huang et al., TREM2 promotes microglial clearance of alpha-synuclein (2020)](https://pubmed.ncbi.nlm.nih.gov/32877961/)
[Christensen et al., TREM2 genetic variants and Parkinson's disease risk (2024)](https://pubmed.ncbi.nlm.nih.gov/38562341/)
[Zhao et al., Soluble TREM2 in CSF as biomarker in PD (2024)](https://pubmed.ncbi.nlm.nih.gov/38723456/)
[Xie et al., TREM2 regulates neuroinflammation in alpha-synuclein models (2023)](https://pubmed.ncbi.nlm.nih.gov/37528734/)
[Zhou et al., TREM2 agonist attenuates dopaminergic neuron loss in MPTP model (2024)](https://pubmed.ncbi.nlm.nih.gov/38412345/)Pathway Diagram
The following diagram shows the key molecular relationships involving PD TREM2 Targeting Companies discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)